ERICH MOHR

Corporate Board Profile

Tech Score: 0/100

Eterna Therapeutics Inc.

Filing Date	Source Excerpt
2021-07-01	Erich Mohr Age: 66 Brooklyn ImmunoTherapeutics Board Service · Tenure: < 1 month (May 2021) · Committees: ○ Audit ○ Nominating and Corporate Governance (Chair) INDEPENDENT
2022-04-26	Erich Mohr, Ph.D., M.Sc., has served on our Board of Directors since May 2021. Dr. Mohr is Founder, Chairman and Chief Executive Officer of MedGensis Therapeutix, Inc., a biopharmaceutical company that commercialized treatments for Parkinson’s disease, a position he has held since 2006. Previously, Dr. Mohr served as Executive Vice President and Chief Scientific Officer of PRA International, a clinical research organization that provided drug development services to pharmaceutical and biotechnology companies. He founded and served as Chairman and Chief Executive Officer of CroMedica International from 1995 to 2002, which later merged with PRA International. Dr. Mohr serves as Chairman of Oak Bar Biosciences, Inc., a developmental biotechnology company focused on treatments for Stargardt disease. Dr. Mohr received a Ph.D. and M.Sc. from the University of Victoria, British Columbia, Canada, and a B.A. and B.Sc. from University of the Pacific. Dr. Mohr’s qualifications to serve on our Board of Directors include his experience in the healthcare industry, his business training and education, and his experience serving on multiple boards over the course of his career. The table below provides current committee membership information and the number of meetings held in 2021: Erich Mohr: Audit Committee member, Compensation Committee member, Nominating and Corporate Governance Committee Chair. 2021 Director Compensation: $390,009.

Filing Date

Source Excerpt

2021-07-01

Erich Mohr Age: 66 Brooklyn ImmunoTherapeutics Board Service · Tenure: < 1 month (May 2021) · Committees: ○ Audit ○ Nominating and Corporate Governance (Chair) INDEPENDENT

2022-04-26

Erich Mohr, Ph.D., M.Sc., has served on our Board of Directors since May 2021. Dr. Mohr is Founder, Chairman and Chief Executive Officer of MedGensis Therapeutix, Inc., a biopharmaceutical company that commercialized treatments for Parkinson’s disease, a position he has held since 2006. Previously, Dr. Mohr served as Executive Vice President and Chief Scientific Officer of PRA International, a clinical research organization that provided drug development services to pharmaceutical and biotechnology companies. He founded and served as Chairman and Chief Executive Officer of CroMedica International from 1995 to 2002, which later merged with PRA International. Dr. Mohr serves as Chairman of Oak Bar Biosciences, Inc., a developmental biotechnology company focused on treatments for Stargardt disease. Dr. Mohr received a Ph.D. and M.Sc. from the University of Victoria, British Columbia, Canada, and a B.A. and B.Sc. from University of the Pacific. Dr. Mohr’s qualifications to serve on our Board of Directors include his experience in the healthcare industry, his business training and education, and his experience serving on multiple boards over the course of his career. The table below provides current committee membership information and the number of meetings held in 2021: Erich Mohr: Audit Committee member, Compensation Committee member, Nominating and Corporate Governance Committee Chair. 2021 Director Compensation: $390,009.

Data sourced from SEC filings. Last updated: 2025-08-30